The predictive biomarkers market size has grown steadily in recent years. It will grow from $20.96 billion in 2025 to $21.88 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to growth in genomic research, rise in targeted therapies, increasing cancer prevalence, expansion of molecular diagnostics, regulatory support for biomarkers.
The predictive biomarkers market size is expected to see steady growth in the next few years. It will grow to $25.65 billion in 2030 at a compound annual growth rate (CAGR) of 4%. The growth in the forecast period can be attributed to advancements in multi-omics technologies, expansion of personalized medicine, increasing pharma R&D spending, demand for predictive treatment outcomes, integration of biomarkers in routine care. Major trends in the forecast period include expansion of precision oncology applications, growing use in drug response stratification, increased biomarker-based clinical trial design, rising companion diagnostics adoption, standardization of biomarker validation protocols.
The rise in cancer cases is increasingly supporting the expansion of the predictive biomarkers market going forward. Cancer is characterized by uncontrolled cell growth with the potential to invade surrounding tissues and spread to other parts of the body. The growing number of cancer cases is associated with aging populations, lifestyle changes, and increased exposure to risk factors such as tobacco use, poor dietary habits, and environmental pollutants. Predictive biomarkers enable clinicians to identify patients who are more likely to respond to specific therapies, supporting personalized and more effective cancer treatment strategies. For example, in April 2024, according to the International Agency for Research on Cancer, a specialized agency of the World Health Organization, nearly 20 million new cancer cases and approximately 10 million cancer-related deaths were reported globally in 2022, with projections indicating annual cases may reach 35 million by 2050. Consequently, the rising burden of cancer is reinforcing growth in the predictive biomarkers market.
Leading companies operating in the predictive biomarkers market are accelerating biomarker development through technological advancements such as artificial intelligence-driven biomarker discovery to gain a competitive advantage. AI-driven biomarker discovery enables the analysis of large and complex datasets, facilitating the identification of predictive biomarkers that may not be detected through traditional approaches. For example, in July 2024, Scipher Medicine Inc., a US-based precision immunology company, launched PRoBeNet (Predictive Response Biomarkers using Network Medicine). This platform is designed to accelerate the discovery of predictive response biomarkers for complex diseases by integrating AI and network biology. PRoBeNet identifies biomarkers associated with therapy response by combining disease-specific molecular signatures with therapy-targeted proteins and has been validated in autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease.
In January 2023, Thermo Fisher Scientific Inc., a US-based biotechnology research company, acquired The Binding Site Group for $2.98 billion. With this acquisition, Thermo Fisher Scientific intends to expand its immunodiagnostics portfolio, strengthen its position in specialty diagnostics, and enhance its capabilities in personalized medicine and disease monitoring solutions. The Binding Site Group is a UK-based diagnostic solutions provider offering predictive biomarkers, particularly in hematology and immunology.
Major companies operating in the predictive biomarkers market are Johnson & Johnson Services Inc, F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthcare GmbH, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Bio-Rad Laboratories Inc, QIAGEN GmbH, Almac Group Limited, ArcherDX Inc, Luminex Corporation, Guardant Health Inc, Meso Scale Diagnostics LLC, Myriad Genetics Inc, NanoString Technologies Inc, Fujirebio Inc, Asuragen Inc, Biognosys AG, Epigenomics AG, OncoCyte Corporation, Biomarker Technologies Inc.
North America was the largest region in the predictive biomarkers market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the predictive biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have moderately impacted the predictive biomarkers market by increasing costs of imported reagents, sequencing tools, and analytical instruments, affecting research laboratories and diagnostic manufacturers. North America and Asia-Pacific, particularly China-based supply chains, face pricing pressures in cancer and metabolic disease segments. However, tariffs are encouraging local manufacturing, regional sourcing, and domestic innovation in biomarker assays and diagnostic platforms.
The predictive biomarkers market research report is one of a series of new reports that provides predictive biomarkers market statistics, including predictive biomarkers industry global market size, regional shares, competitors with a predictive biomarkers market share, detailed predictive biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the predictive biomarkers industry. This predictive biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Predictive biomarkers are biological indicators that help forecast an individual’s risk of developing a disease or their likely response to a particular treatment. They may include genetic, protein-based, or molecular markers that offer insights into disease risk or treatment effectiveness, allowing therapies to be tailored to individual patients and potentially improving outcomes while reducing unnecessary side effects.
The key indication categories of predictive biomarkers include cancer, metabolic diseases, cardiovascular disorders, immunological disorders, and others. Predictive biomarkers in cancer are used to assess an individual’s risk of developing cancer or to predict response to specific cancer therapies and may include genetic mutations, protein expression levels, or other biological indicators. The applications include screening, analysis, diagnosis, prediction, and monitoring, and the end users include diagnostic centers, contract research organizations, academic research institutions, pharmaceutical companies, biotechnology firms, and others.
The predictive biomarkers market consists of revenues earned by entities by providing services such as biomarker discovery, validation, and testing, as well as genetic screening, data analysis, and personalized medicine solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The predictive biomarkers market also includes sales of genetic testing kits, molecular diagnostic assays, genomic sequencing tools, and bioinformatics software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The predictive biomarkers market size is expected to see steady growth in the next few years. It will grow to $25.65 billion in 2030 at a compound annual growth rate (CAGR) of 4%. The growth in the forecast period can be attributed to advancements in multi-omics technologies, expansion of personalized medicine, increasing pharma R&D spending, demand for predictive treatment outcomes, integration of biomarkers in routine care. Major trends in the forecast period include expansion of precision oncology applications, growing use in drug response stratification, increased biomarker-based clinical trial design, rising companion diagnostics adoption, standardization of biomarker validation protocols.
The rise in cancer cases is increasingly supporting the expansion of the predictive biomarkers market going forward. Cancer is characterized by uncontrolled cell growth with the potential to invade surrounding tissues and spread to other parts of the body. The growing number of cancer cases is associated with aging populations, lifestyle changes, and increased exposure to risk factors such as tobacco use, poor dietary habits, and environmental pollutants. Predictive biomarkers enable clinicians to identify patients who are more likely to respond to specific therapies, supporting personalized and more effective cancer treatment strategies. For example, in April 2024, according to the International Agency for Research on Cancer, a specialized agency of the World Health Organization, nearly 20 million new cancer cases and approximately 10 million cancer-related deaths were reported globally in 2022, with projections indicating annual cases may reach 35 million by 2050. Consequently, the rising burden of cancer is reinforcing growth in the predictive biomarkers market.
Leading companies operating in the predictive biomarkers market are accelerating biomarker development through technological advancements such as artificial intelligence-driven biomarker discovery to gain a competitive advantage. AI-driven biomarker discovery enables the analysis of large and complex datasets, facilitating the identification of predictive biomarkers that may not be detected through traditional approaches. For example, in July 2024, Scipher Medicine Inc., a US-based precision immunology company, launched PRoBeNet (Predictive Response Biomarkers using Network Medicine). This platform is designed to accelerate the discovery of predictive response biomarkers for complex diseases by integrating AI and network biology. PRoBeNet identifies biomarkers associated with therapy response by combining disease-specific molecular signatures with therapy-targeted proteins and has been validated in autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease.
In January 2023, Thermo Fisher Scientific Inc., a US-based biotechnology research company, acquired The Binding Site Group for $2.98 billion. With this acquisition, Thermo Fisher Scientific intends to expand its immunodiagnostics portfolio, strengthen its position in specialty diagnostics, and enhance its capabilities in personalized medicine and disease monitoring solutions. The Binding Site Group is a UK-based diagnostic solutions provider offering predictive biomarkers, particularly in hematology and immunology.
Major companies operating in the predictive biomarkers market are Johnson & Johnson Services Inc, F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthcare GmbH, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Bio-Rad Laboratories Inc, QIAGEN GmbH, Almac Group Limited, ArcherDX Inc, Luminex Corporation, Guardant Health Inc, Meso Scale Diagnostics LLC, Myriad Genetics Inc, NanoString Technologies Inc, Fujirebio Inc, Asuragen Inc, Biognosys AG, Epigenomics AG, OncoCyte Corporation, Biomarker Technologies Inc.
North America was the largest region in the predictive biomarkers market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the predictive biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have moderately impacted the predictive biomarkers market by increasing costs of imported reagents, sequencing tools, and analytical instruments, affecting research laboratories and diagnostic manufacturers. North America and Asia-Pacific, particularly China-based supply chains, face pricing pressures in cancer and metabolic disease segments. However, tariffs are encouraging local manufacturing, regional sourcing, and domestic innovation in biomarker assays and diagnostic platforms.
The predictive biomarkers market research report is one of a series of new reports that provides predictive biomarkers market statistics, including predictive biomarkers industry global market size, regional shares, competitors with a predictive biomarkers market share, detailed predictive biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the predictive biomarkers industry. This predictive biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Predictive biomarkers are biological indicators that help forecast an individual’s risk of developing a disease or their likely response to a particular treatment. They may include genetic, protein-based, or molecular markers that offer insights into disease risk or treatment effectiveness, allowing therapies to be tailored to individual patients and potentially improving outcomes while reducing unnecessary side effects.
The key indication categories of predictive biomarkers include cancer, metabolic diseases, cardiovascular disorders, immunological disorders, and others. Predictive biomarkers in cancer are used to assess an individual’s risk of developing cancer or to predict response to specific cancer therapies and may include genetic mutations, protein expression levels, or other biological indicators. The applications include screening, analysis, diagnosis, prediction, and monitoring, and the end users include diagnostic centers, contract research organizations, academic research institutions, pharmaceutical companies, biotechnology firms, and others.
The predictive biomarkers market consists of revenues earned by entities by providing services such as biomarker discovery, validation, and testing, as well as genetic screening, data analysis, and personalized medicine solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The predictive biomarkers market also includes sales of genetic testing kits, molecular diagnostic assays, genomic sequencing tools, and bioinformatics software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Predictive Biomarkers Market Characteristics
3. Predictive Biomarkers Market Supply Chain Analysis
4. Global Predictive Biomarkers Market Trends and Strategies
5. Predictive Biomarkers Market Analysis of End Use Industries
7. Global Predictive Biomarkers Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Predictive Biomarkers Total Addressable Market (TAM) Analysis for the Market
9. Predictive Biomarkers Market Segmentation
10. Predictive Biomarkers Market Regional and Country Analysis
11. Asia-Pacific Predictive Biomarkers Market
12. China Predictive Biomarkers Market
13. India Predictive Biomarkers Market
14. Japan Predictive Biomarkers Market
15. Australia Predictive Biomarkers Market
16. Indonesia Predictive Biomarkers Market
17. South Korea Predictive Biomarkers Market
18. Taiwan Predictive Biomarkers Market
19. South East Asia Predictive Biomarkers Market
20. Western Europe Predictive Biomarkers Market
21. UK Predictive Biomarkers Market
22. Germany Predictive Biomarkers Market
23. France Predictive Biomarkers Market
24. Italy Predictive Biomarkers Market
25. Spain Predictive Biomarkers Market
26. Eastern Europe Predictive Biomarkers Market
27. Russia Predictive Biomarkers Market
28. North America Predictive Biomarkers Market
29. USA Predictive Biomarkers Market
30. Canada Predictive Biomarkers Market
31. South America Predictive Biomarkers Market
32. Brazil Predictive Biomarkers Market
33. Middle East Predictive Biomarkers Market
34. Africa Predictive Biomarkers Market
36. Predictive Biomarkers Market Competitive Landscape and Company Profiles
37. Predictive Biomarkers Market Other Major and Innovative Companies
40. Predictive Biomarkers Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Predictive Biomarkers Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses predictive biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for predictive biomarkers? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The predictive biomarkers market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Cancer; Metabolic Disease; Cardiovascular Disorder; Immunological Disorder; Other Indications2) By Application: Screening; Analysis; Diagnosis; Prediction; Monitoring
3) By End User: Diagnostic Centers; Contract Research Organizations; Academic Research Institutes; Pharms And Biotech Companies; Other End Users
Subsegments:
1) By Cancer: Breast Cancer; Lung Cancer; Prostate Cancer; Colorectal Cancer; Ovarian Cancer; Leukemia And Lymphoma; Melanoma; Pancreatic Cancer; Kidney Cancer; Head And Neck Cancer2) By Metabolic Disease: Type 1 And Type 2 Diabetes; Obesity; Metabolic Syndrome; Non-Alcoholic Fatty Liver Disease (NAFLD); Dyslipidemia; Insulin Resistance
3) By Cardiovascular Disorder: Atherosclerosis; Coronary Artery Disease; Heart Failure; Myocardial Infarction (Heart Attack); Arrhythmia; Hypertension; Stroke; Peripheral Arterial Disease
4) By Immunological Disorder: Autoimmune Diseases; Inflammatory Bowel Disease (Ibd); Multiple Sclerosis; Psoriasis; Allergic Diseases; Asthma; Chronic Obstructive Pulmonary Disease (Copd); Immunodeficiency Disorders
5) By Other Indications: Neurological Disorders; Infectious Diseases; Renal Diseases; Osteoarthritis; Genetic Disorders; Respiratory Disorders
Companies Mentioned: Johnson & Johnson Services Inc; F Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc; Abbott Laboratories; Danaher Corporation; Merck KGaA; Siemens Healthcare GmbH; Agilent Technologies Inc; PerkinElmer Inc; Illumina Inc; Bio-Rad Laboratories Inc; QIAGEN GmbH; Almac Group Limited; ArcherDX Inc; Luminex Corporation; Guardant Health Inc; Meso Scale Diagnostics LLC; Myriad Genetics Inc; NanoString Technologies Inc; Fujirebio Inc; Asuragen Inc; Biognosys AG; Epigenomics AG; OncoCyte Corporation; Biomarker Technologies Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Predictive Biomarkers market report include:- Johnson & Johnson Services Inc
- F Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc
- Abbott Laboratories
- Danaher Corporation
- Merck KGaA
- Siemens Healthcare GmbH
- Agilent Technologies Inc
- PerkinElmer Inc
- Illumina Inc
- Bio-Rad Laboratories Inc
- QIAGEN GmbH
- Almac Group Limited
- ArcherDX Inc
- Luminex Corporation
- Guardant Health Inc
- Meso Scale Diagnostics LLC
- Myriad Genetics Inc
- NanoString Technologies Inc
- Fujirebio Inc
- Asuragen Inc
- Biognosys AG
- Epigenomics AG
- OncoCyte Corporation
- Biomarker Technologies Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 21.88 Billion |
| Forecasted Market Value ( USD | $ 25.65 Billion |
| Compound Annual Growth Rate | 4.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
